US SB205 | 2019-2020 | 116th Congress

Status

Spectrum: Moderate Partisan Bill (Democrat 9-2)
Status: Introduced on January 24 2019 - 25% progression, died in committee
Action: 2019-01-24 - Read twice and referred to the Committee on Finance.
Pending: Senate Finance Committee
Text: Latest bill text (Introduced) [PDF]

Summary

Requires drug manufacturers with Medicaid rebate agreements for covered outpatient drugs to disclose drug product information. Manufacturers are subject to civil penalties for knowingly misclassifying drugs. Manufacturers are also required to compensate for rebates that were initially underpaid as a result of misclassification (whether or not such misclassification was committed knowingly).

Tracking Information

Register now for our free OneVote public service or GAITS Pro trial account and you can begin tracking this and other legislation, all driven by the real-time data of the LegiScan API. Providing tools allowing you to research pending legislation, stay informed with email alerts, content feeds, and share dynamic reports. Use our new PolitiCorps to join with friends and collegaues to monitor & discuss bills through the process.

Monitor Legislation or view this same bill number from multiple sessions or take advantage of our national legislative search.

Title

Right Rebate Act of 2019

Sponsors


History

DateChamberAction
2019-01-24SenateRead twice and referred to the Committee on Finance.

Same As/Similar To

HB937 (Related) 2019-01-31 - Referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
HB1839 (Related) 2019-04-18 - Became Public Law No: 116-16. (TXT | PDF)

Subjects


US Congress State Sources


Bill Comments

feedback